[Federal Register Volume 85, Number 173 (Friday, September 4, 2020)]
[Notices]
[Page 55308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19621]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Charter Renewal

    In accordance with Title 41 of the U.S. Code of Federal 
Regulations, Section 102-3.65(a), notice is hereby given that the 
Charter for the National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee was renewed for an additional 
two-year period on April 14, 2020.
    It is determined that the National Cancer Institute Clinical Trials 
and Translational Research Advisory Committee is in the public interest 
in connection with the performance of duties imposed on the National 
Cancer Institute and National Institutes of Health by law, and that 
these duties can best be performed through the advice and counsel of 
this group.
    Inquiries may be directed to Claire Harris, Director, Office of 
Federal Advisory Committee Policy, Office of the Director, National 
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, 
Maryland 20892 (Mail Stop Code 4875), [email protected] or Telephone 
(301) 496-2123.

    Dated: September 1, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-19621 Filed 9-3-20; 8:45 am]
BILLING CODE 4140-01-P